Korro Bio reports Q3 net loss $21M, cash $169.1M; files clinical study for KRRO-110, partners Novo Nordisk

Korro Bio, Inc.

2024-Q3 EPS reported -$7.11

Net loss of $21.0M for Q3 2024 vs $18.5M in Q3 2023; R&D expenses $16.0M (up from $14.0M).
Cash and equivalents $169.1M as of Sep 30, 2024; cash runway into H2 2026.
Submitted regulatory filing in Australia for Phase 1/2 study of KRRO-110 in AATD; first dosing expected Q1 2025.
Announced collaboration with Novo Nordisk for up to two targets in cardiometabolic diseases; up to $530M in milestones plus royalties.
Appointed Jeffrey Cerio as General Counsel, Katharine Knobil to Board; formed Clinical Advisory Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.